All In Biotech

Drug Trial Radar · NCT01191723

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

A Randomized, Double Blind, Placebo Controlled, Three- Period Crossover Study Comparing the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo on QT Intervals in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jan 9, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

54

Actual

Start

Aug 2010

Primary completion

Sep 2010

Study completion Sep 2010

Sponsor

Lead sponsor
AllerganAbbVie (ABBV)
Sponsor type
Industry
Collaborators
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan
First posted
Aug 31, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Compare the acute effect on the QT interval of MAP0004 (Dihydroergotamine Mesylate delivered by Oral Inhalation) with Moxifloxacin and Placebo.

Conditions

  • Healthy

Interventions

  • MAP0004Drug

    3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol

  • Inhaler PlaceboDrug

    Placebo for Inhaler administered in Treatments A and C

  • MoxifloxacinDrug

    400mg encapsulated tablet administered in Treatment A as per protocol

  • Placebo CapsuleDrug

    Placebo for Moxifloxacin administered in Treatment B and Treatment C

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in QTcI for MAP0004 3.0mg and Placebo at 30 MinutesTime frame: baseline and 30 minutes
  2. Change From Baseline in QTcI for MAP0004 3.0mg, Placebo, and Moxifloxacin at 2 HoursTime frame: baseline and 2 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cetero Research

    Fargo, North Dakota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.